Current Knowledge About Aprocitentan in Hypertension

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Therapeutics

Background:

• Hypertension (HT) is a leading global health issue, increasing cardiovascular disease (CVD) risk.
• HT is a modifiable risk factor, necessitating novel therapeutic strategies.
• Rising life expectancy and obesity rates are exacerbating the global hypertension burden.

Purpose of the Study:

• To review current knowledge on aprocitentan (ACT) for hypertension management.
• To explore ACT's pharmacological mechanisms and therapeutic potential.
• To assess ACT's role in addressing resistant hypertension.

Main Methods:

• Conducted a literature search on PubMed and ClinicalTrials.gov.
• Utilized search terms including "hypertension", "aprocitentan", "high blood pressure", and "cardiovascular disease".
• Reviewed human and animal studies on ACT's efficacy and safety.

Main Results:

• ACT demonstrated significant blood pressure reduction within 14 days in human and animal studies.
• The optimal effective dose identified was 25 mg, with no severe adverse effects reported.
• ACT showed compatibility with other antihypertensive agents, sometimes yielding synergistic effects.

Conclusions:

• Aprocitentan (ACT) is a promising dual endothelin receptor antagonist for hypertension.
• ACT may play a key role in managing resistant hypertension due to its unique mechanism of action.
• Its compatibility with existing therapies suggests potential for combination use in complex cases.